Matthew Mei

3.9k total citations
108 papers, 1.1k citations indexed

About

Matthew Mei is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Matthew Mei has authored 108 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 58 papers in Pathology and Forensic Medicine and 24 papers in Genetics. Recurrent topics in Matthew Mei's work include Lymphoma Diagnosis and Treatment (56 papers), CAR-T cell therapy research (45 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Matthew Mei is often cited by papers focused on Lymphoma Diagnosis and Treatment (56 papers), CAR-T cell therapy research (45 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Matthew Mei collaborates with scholars based in United States, Germany and Chile. Matthew Mei's co-authors include Stephen J. Forman, Alex F. Herrera, Ibrahim Aldoss, Vinod Pullarkat, Guido Marcucci, Leslie Popplewell, Larry W. Kwak, Steven T. Rosen, Ryotaro Nakamura and Lihua E. Budde and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Matthew Mei

91 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Mei United States	20	523	391	292	286	216	108	1.1k
Simone Ferrero Italy	18	462 0.9×	583 1.5×	270 0.9×	390 1.4×	347 1.6×	82	1.3k
Stanley Frankel United States	13	424 0.8×	362 0.9×	240 0.8×	211 0.7×	514 2.4×	24	1.2k
Cristiana Carniti Italy	21	439 0.8×	245 0.6×	169 0.6×	392 1.4×	396 1.8×	59	1.2k
Hyeon‐Seok Eom South Korea	24	864 1.7×	679 1.7×	301 1.0×	530 1.9×	412 1.9×	133	1.7k
Mark Bishton United Kingdom	20	507 1.0×	477 1.2×	214 0.7×	209 0.7×	686 3.2×	71	1.3k
Gareth P. Gregory Australia	16	495 0.9×	421 1.1×	221 0.8×	184 0.6×	290 1.3×	74	956
Yair Herishanu Israel	15	279 0.5×	213 0.5×	207 0.7×	175 0.6×	265 1.2×	36	1.0k
Sheeja T. Pullarkat United States	13	508 1.0×	272 0.7×	113 0.4×	116 0.4×	234 1.1×	43	980
Gisele W. B. Colleoni Brazil	21	590 1.1×	348 0.9×	152 0.5×	432 1.5×	678 3.1×	85	1.5k
Jan B. Egan United States	16	448 0.9×	436 1.1×	216 0.7×	709 2.5×	868 4.0×	34	1.6k

Countries citing papers authored by Matthew Mei

Since Specialization

Citations

This map shows the geographic impact of Matthew Mei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Mei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Mei more than expected).

Fields of papers citing papers by Matthew Mei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Mei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Mei. The network helps show where Matthew Mei may publish in the future.

Co-authorship network of co-authors of Matthew Mei

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Mei. A scholar is included among the top collaborators of Matthew Mei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Mei. Matthew Mei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mei, Matthew, Joycelynne Palmer, Hun Ju Lee, et al.. (2025). Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma. HemaSphere. 9(5). e70126–e70126.

Xiao, Annie, Lu Chen, Matthew Mei, et al.. (2025). Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma. Leukemia & lymphoma. 66(12). 2260–2268.

Ladbury, Colton, Sagus Sampath, Jeffrey Wong, et al.. (2024). Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy. Frontiers in Immunology. 15. 1419788–1419788. 1 indexed citations

Maakaron, Joseph, Dipenkumar Modi, Matthew Mei, et al.. (2024). Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study. Blood. 144(Supplement 1). 3052–3052. 2 indexed citations

Goldsmith, Scott, Geoffrey Shouse, F. Lennie Wong, et al.. (2024). Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy. Transplantation and Cellular Therapy. 30(9). 927.e1–927.e9. 5 indexed citations

Stuver, Robert, Esther Drill, Nivetha Ganesan, et al.. (2023). Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies. Blood. 142(Supplement 1). 3069–3069. 1 indexed citations

Ong, Shin Yeu, Matthew Mei, Leslie Popplewell, et al.. (2023). Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma. American Journal of Hematology. 98(11). 1751–1761. 17 indexed citations

Ahmed, Sairah, Matthew Mei, David M. Kurtz, et al.. (2023). Combined autologous CD30.CAR‐T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study). Hematological Oncology. 41(S2). 524–525.

Palomba, Maria Lia, Matthew Mei, Paolo F. Caimi, et al.. (2023). Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory  CD19 expressing hematologic malignancies (NCT05665062). Cancer Research. 83(8_Supplement). CT125–CT125. 3 indexed citations

10.

Goldsmith, Scott, Geoffrey Shouse, F. Lennie Wong, et al.. (2023). Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Blood. 142(Supplement 1). 4814–4814.

11.

Saumoy, Monica, Yecheskel Schneider, Lihua E. Budde, et al.. (2022). Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood. 140(25). 2697–2708. 14 indexed citations

12.

Malki, Monzr M. Al, Joycelynne Palmer, Ni‐Chun Tsai, et al.. (2022). Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Advances. 6(14). 4098–4106. 15 indexed citations

13.

Mei, Matthew, Lisa Masucci, & Michael D. Jain. (2022). Cellular therapy: Great promise, but at what cost?. Molecular Therapy. 31(1). 5–6. 1 indexed citations

14.

Aldoss, Ibrahim, Jianying Zhang, Matthew Mei, et al.. (2020). Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia. American Journal of Hematology. 95(10). 1193–1199. 27 indexed citations

15.

Gupta, Rohan, Idoroenyi Amanam, Chen Chen, et al.. (2020). Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital. Clinical Lymphoma Myeloma & Leukemia. 20(6). e320–e327. 5 indexed citations

16.

Chen, Robert, Alex F. Herrera, Lu Chen, et al.. (2019). Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. Clinical Cancer Research. 26(5). 1034–1044. 61 indexed citations

17.

Slavin, Thomas P., Jennifer Berano Teh, Jeffrey N. Weitzel, et al.. (2019). Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 25(12). 2517–2521. 18 indexed citations

18.

Chen, Robert W., Joycelynne Palmer, Alex F. Herrera, et al.. (2017). Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. Blood. 130(Suppl_1). 738–738. 6 indexed citations

19.

Mukherjea, Arnab, et al.. (2016). A Novel Method for Evaluating Value Assessment Frameworks. Value in Health. 19(7). A376–A376.

20.

Mei, Matthew, Sandra H. Thomas, & Robert Chen. (2013). Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody–Drug Conjugates: Focus on Brentuximab Vedotin. BioDrugs. 28(3). 245–251. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact